← All trials
NCT02966652
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2016
- Primary completion
- Nov 1, 2017
- Completion date
- Nov 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Diurnal LimitedLead sponsor
- Sheffield Hallam UniversityOverall official - principal investigator
- University of ManchesterCollaborator
- Sheffield Hallam UniversityCollaborator
- Simbec-OrionCollaborator
- Medical Matters InternationalCollaborator
- Voet ConsultingCollaborator
- Envigo Pharma Consulting LimitedCollaborator
- Emas Pharma Ltd.Collaborator
- Brush Clinical Research Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.